Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
News for Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) centers on its role as a commercial-stage medical dermatology and biopharmaceutical company focused on immune-mediated skin diseases. Company announcements frequently highlight developments in its ZORYVE (roflumilast) topical franchise for atopic dermatitis, plaque psoriasis, and seborrheic dermatitis, along with updates on its broader immuno-dermatology pipeline.
Investors and clinicians following ARQT news can expect detailed coverage of regulatory milestones, such as U.S. Food and Drug Administration (FDA) approvals and supplemental new drug application (sNDA) acceptances for new age groups and indications. Releases describe label expansions for ZORYVE cream and foam, including approvals for pediatric atopic dermatitis and seborrheic dermatitis, and FDA review timelines for potential new pediatric plaque psoriasis indications.
Arcutis also reports on clinical trial progress and data presentations. Recent news includes completion of enrollment in pediatric studies like INTEGUMENT-INFANT, publication of long-term safety and efficacy data for ZORYVE foam 0.3% in seborrheic dermatitis, and new Phase 3 analyses showing improvements in itch, sleep disruption, and long-term disease control with ZORYVE cream 0.15% and 0.05% in atopic dermatitis.
Financial and corporate updates form another key news category. The company issues quarterly earnings releases detailing net product revenue for ZORYVE, outlines strategies for sustainable growth, and provides guidance on future net product sales. Additional items include inducement equity grants, participation in investor conferences, and board-level changes disclosed via press releases and Form 8-K filings.
News flow also covers pipeline and strategic priorities, such as Phase 2 proof-of-concept trials of ZORYVE foam 0.3% in vitiligo and hidradenitis suppurativa, and early clinical development plans for ARQ-234, a CD200 receptor checkpoint agonist being developed as a potential biologic for atopic dermatitis. Together, these updates give readers insight into Arcutis’ commercial performance, regulatory trajectory, and ongoing research in immuno-dermatology.
Arcutis (Nasdaq: ARQT) has begun enrolling the first participant in a Phase 1a/1b first‑in‑human study (ARQ-234-131) of ARQ-234, a CD200R agonist fusion protein for moderate to severe atopic dermatitis.
The double‑blind, randomized, placebo‑controlled study will assess safety and tolerability in single‑ascending and multiple‑ascending dose cohorts in healthy volunteers and adults with atopic dermatitis, plus a small proof‑of‑concept cohort. ARQ-234 is administered subcutaneously and is designed to selectively activate CD200R to modulate overactive immune responses.
Arcutis (Nasdaq: ARQT) announced management will present at the TD Cowen 46th Annual Health Care Conference in Boston, March 2-4, 2026. The company will host a Fireside Chat on March 2, 2026 at 1:50 p.m. ET.
The live webcast is available via the company Events page and a replay will remain accessible on the Arcutis website for 180 days following the conference.
Arcutis (Nasdaq: ARQT) reported strong commercial momentum for ZORYVE with Q4 2025 net product revenue of $127.5M (up 84% YoY, +29% sequential) and full-year 2025 net product revenue of $372.1M (up 123% YoY). The company generated $26.2M operating cash flow in Q4, raised 2026 net product sales guidance to $480–$495M, and expects an sNDA submission for ZORYVE cream 0.05% in infants in Q2 2026.
Arcutis also expanded its dermatology sales force, secured broader Medicare access, and holds cash and marketable securities of $221.3M as of Dec 31, 2025.
Arcutis (Nasdaq: ARQT) announced that professional golfer Max Homa joined its Free to Be Me awareness campaign to encourage people with seborrheic dermatitis to seek long-term treatment. The company highlights ZORYVE foam 0.3%, indicated for ages 9+, showing rapid clearance and itch relief in clinical trials.
In trials, 77% achieved clear/almost clear skin at 8 weeks versus 53% for inactive foam; itch relief reached nearly 63% versus 41%. ZORYVE is steroid-free, leave-in, and reported common side effects ≥1% (common cold, nausea, headache).
Arcutis Biotherapeutics (Nasdaq: ARQT) reported inducement awards: an aggregate of 94,000 restricted stock units granted to 12 newly hired employees with a grant date of February 2, 2026. The RSUs vest over four years with 25% vesting on each annual anniversary and were approved by the Compensation Committee under the 2022 Inducement Plan, disclosed in accordance with Nasdaq Listing Rule 5635(c)(4).
Arcutis (Nasdaq: ARQT) reported positive topline results from the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% (roflumilast) in infants 3 months to <24 months with mild–moderate atopic dermatitis. At Week 4, 58% of participants achieved EASI-75. The cream was well tolerated with no new safety signals through four weeks. The company plans an sNDA submission in Q2 2026 for this age group.
Arcutis (Nasdaq: ARQT) announced on January 23, 2026 that it and Kowa mutually agreed to terminate their promotion agreement for ZORYVE promotion to primary care physicians and pediatricians in the U.S.
Arcutis will assume responsibility for sales and promotion to those clinicians, is finalizing promotional plans, and will provide further detail on the Q4 earnings call on February 25, 2026. Under the termination, Kowa will stop promotion and Arcutis will not be required to make any further payments. The company expects to remain cash flow break even and does not expect the change to negatively affect 2026 net product sales guidance.
Arcutis Biotherapeutics (Nasdaq: ARQT) will report its fourth quarter and full year 2025 financial results and provide a business update on Wednesday, February 25, 2026 after U.S. market close. The company will host a conference call and webcast the same day at 4:30 p.m. ET, with presentation materials available in the company Events section and an archived replay posted afterward.
Arcutis management will also present at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026 with a fireside chat at 11:30 a.m. ET; that webcast and a replay will be accessible via the company Events page for 180 days.
Arcutis Biotherapeutics (Nasdaq: ARQT) on Jan 21, 2026 published nationwide survey results showing high patient concern about topical steroid use and a preference gap toward proactive long‑term management for chronic inflammatory skin diseases. Key findings: 88% of adults and 91% of parents reported concern about steroid side effects; 72% of adults and 80% of children experienced uncontrolled disease at least monthly; and only 20% of adults are completely confident in current treatments. The survey highlights emotional, social, and daily‑life impacts and indicates demand for safe, effective non‑steroidal long‑term options.
Arcutis (Nasdaq: ARQT) outlined 2026 strategic priorities focused on expanding the commercial footprint of ZORYVE and advancing its pipeline. Management reiterated full-year ZORYVE net product sales guidance of $455–$470 million and plans a targeted ~20% dermatology sales force expansion. Key development milestones include topline INTEGUMENT-INFANT Phase 2 results in Q1 2026 and an expected sNDA submission in Q3 2026 for ZORYVE cream 0.05% in infants; an FDA PDUFA target action date of June 29, 2026 for the sNDA for ZORYVE cream 0.3% in ages 2–5; Phase 2 proof‑of‑concept trials in vitiligo and hidradenitis suppurativa with program decisions in Q4 2026 and Q1 2027; and initiation of Phase 1 enrollment for ARQ-234 in Q1 2026. The company cited a transition to positive cash flows to fund growth and pipeline investment.